"Breast Neoplasms, Male" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.
| Descriptor ID |
D018567
|
| MeSH Number(s) |
C04.588.180.260 C17.800.090.500.260
|
| Concept/Terms |
Breast Neoplasms, Male- Breast Neoplasms, Male
- Breast Neoplasm, Male
- Male Breast Neoplasm
- Neoplasm, Male Breast
- Tumors, Breast, Male
- Neoplasms, Breast, Male
- Neoplasms, Male Breast
- Breast Tumors, Male
- Breast Tumor, Male
- Male Breast Tumor
- Male Breast Tumors
- Tumor, Male Breast
- Tumors, Male Breast
- Male Breast Neoplasms
Male Breast Cancer- Male Breast Cancer
- Cancer, Male Breast
- Breast Carcinoma, Male
- Carcinoma, Male Breast
- Male Breast Carcinoma
- Breast Cancer, Male
|
Below are MeSH descriptors whose meaning is more general than "Breast Neoplasms, Male".
Below are MeSH descriptors whose meaning is more specific than "Breast Neoplasms, Male".
This graph shows the total number of publications written about "Breast Neoplasms, Male" by people in this website by year, and whether "Breast Neoplasms, Male" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 1 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2009 | 2 | 0 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Breast Neoplasms, Male" by people in Profiles.
-
Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution. Clin Breast Cancer. 2020 12; 20(6):520-526.
-
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer. 2019 06; 120(12):1105-1112.
-
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. J Med Genet. 2016 07; 53(7):465-71.
-
Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. J Clin Oncol. 2015 Jul 10; 33(20):2239-45.
-
Primary neuroendocrine carcinoma of the breast: clinical, imaging, and histologic features. AJR Am J Roentgenol. 2014 Aug; 203(2):W221-30.
-
Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer. 2014 May 27; 110(11):2756-64.
-
Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Oct; 141(3):461-70.
-
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct; 24 Suppl 6:vi7-23.
-
Male breast cancer according to tumor subtype and race: a population-based study. Cancer. 2013 May 01; 119(9):1611-7.
-
Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2012 Sep; 135(2):619-27.